Formosa Pharmaceuticals Pipeline


APP13002, also derived from our proprietary APNT formulation platform, is another aqueous-based ophthalmic nanosuspension utilizing a potent antibiotic known for its broad spectrum of antibacterial activity. This formulation, which represents a novel application of the known API, targets infectious eye diseases such as blepharitis, and also has a mechanism of action that lends itself well to the treatment of dry-eye syndrome.  APP13002 has the potential for combination therapies with other eye therapies, such as APP13007.

Formosa Pharmaceuticals’ Pipeline

Scroll to Top